{"id":95468,"date":"2025-09-24T19:42:52","date_gmt":"2025-09-24T22:42:52","guid":{"rendered":"https:\/\/med.estrategia.com\/portal\/?p=95468"},"modified":"2025-09-24T20:13:41","modified_gmt":"2025-09-24T23:13:41","slug":"estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1","status":"publish","type":"post","link":"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/","title":{"rendered":"Estudo in\u00e9dito testa Dolutegravir contra transmiss\u00e3o vertical do HTLV-1"},"content":{"rendered":"<p>A <strong>Funda&ccedil;&atilde;o Oswaldo Cruz (Fiocruz)<\/strong>, por meio de sua unidade da Bahia, e o <strong>Minist&eacute;rio da Sa&uacute;de<\/strong> deram in&iacute;cio a um estudo cl&iacute;nico in&eacute;dito no Brasil para avaliar uma nova estrat&eacute;gia de preven&ccedil;&atilde;o contra a transmiss&atilde;o vertical do v&iacute;rus linfotr&oacute;pico de c&eacute;lulas T humanas tipo 1 (HTLV-1). A pesquisa, batizada de <strong>PrevINIr HTLV-TV<\/strong>, investigar&aacute; o <strong>uso do dolutegravir para impedir que gestantes infectadas transmitam o v&iacute;rus aos filhos<\/strong> durante a gravidez ou parto. O medicamento &eacute; indicado no tratamento da infec&ccedil;&atilde;o pelo HIV (v&iacute;rus da imunodefici&ecirc;ncia humana).<p>Atualmente, <strong>o Brasil adota medidas preventivas<\/strong> como a testagem obrigat&oacute;ria de gestantes no pr&eacute;-natal e a recomenda&ccedil;&atilde;o para que m&atilde;es infectadas pelo HTLV-1 n&atilde;o amamentem, fornecendo gratuitamente f&oacute;rmula infantil &agrave;s crian&ccedil;as expostas. Apesar disso, existe um <strong>risco residual estimado em 5%<\/strong> de transmiss&atilde;o durante a gesta&ccedil;&atilde;o ou o parto. Caso o dolutegravir comprove efic&aacute;cia, esta ser&aacute; a <strong>primeira interven&ccedil;&atilde;o farmacol&oacute;gica mundial<\/strong> com esse objetivo, representando um avan&ccedil;o hist&oacute;rico para a sa&uacute;de p&uacute;blica.<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_79_2 counter-hierarchy ez-toc-counter ez-toc-transparent ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\"><p class=\"ez-toc-title\" style=\"cursor:inherit\">Navegue pelo conte\u00fado<\/p>\n<\/div><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/#O-que-e-o-HTLV-1\" >O que &eacute; o HTLV-1<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/#Como-funcionara-o-estudo\" >Como funcionar&aacute; o estudo<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-o-que-e-o-htlv-1\"><span class=\"ez-toc-section\" id=\"O-que-e-o-HTLV-1\"><\/span>O que &eacute; o HTLV-1<span class=\"ez-toc-section-end\"><\/span><\/h2><p>O HTLV-1 &eacute; um <strong>retrov&iacute;rus que compromete o sistema imunol&oacute;gico<\/strong>, fazendo com que suas c&eacute;lulas percam a fun&ccedil;&atilde;o de defender o organismo. Dentre as formas de transmiss&atilde;o do tipo 1 est&atilde;o: <\/p><ul class=\"wp-block-list\">\n<li><strong>Tranmiss&atilde;o vertical de m&atilde;e para o filho<\/strong>, durante gesta&ccedil;&atilde;o, partou ou amamenta&ccedil;&atilde;o;<\/li>\n\n\n\n<li>Rela&ccedil;&atilde;o sexual desprotegida com parceiro infectado; e<\/li>\n\n\n\n<li>Compartilhamento de seringas e agulhas.<\/li>\n<\/ul><p>Este subtipo est&aacute; associado a doen&ccedil;as graves, como a leucemia\/linfoma de c&eacute;lulas T do adulto e a mielopatia associada ao HTLV, al&eacute;m de elevar o risco de contrair outras infec&ccedil;&otilde;es.<\/p><h2 class=\"wp-block-heading\" id=\"h-como-funcionara-o-estudo\"><span class=\"ez-toc-section\" id=\"Como-funcionara-o-estudo\"><\/span>Como funcionar&aacute; o estudo<span class=\"ez-toc-section-end\"><\/span><\/h2><p>Segundo nota publicada pela Ag&ecirc;ncia Fiocruz de Not&iacute;cias, o ensaio cl&iacute;nico ser&aacute; um estudo randomizado de fase 2\/3 que acompanhar&aacute; <strong>516 gestantes com HTLV-1<\/strong> <strong>e seus beb&ecirc;s at&eacute; os 18 meses de idade<\/strong>. As participantes ser&atilde;o divididas em dois grupos:<\/p><ul class=\"wp-block-list\">\n<li><strong>Grupo 1<\/strong> &ndash; receber&atilde;o cuidado padr&atilde;o mais dose de dolutegravir de 50 mg\/dia a partir da 24&ordf; semana de gesta&ccedil;&atilde;o at&eacute; o parto; j&aacute; os rec&eacute;m-nascidos receber&atilde;o 5 mg\/dia do medicamento durante 28 dias.<br><\/li>\n\n\n\n<li><strong>Grupo 2<\/strong> &ndash; seguir&atilde;o apenas a recomenda&ccedil;&atilde;o atual de n&atilde;o amamenta&ccedil;&atilde;o.<\/li>\n<\/ul><p>Todos os pares passar&atilde;o por <strong>acompanhamento cl&iacute;nico e laboratorial<\/strong>, incluindo avalia&ccedil;&atilde;o de carga proviral, anticorpos anti-HTLV-1 e fun&ccedil;&atilde;o hep&aacute;tica e renal.&nbsp;<\/p><p>Ainda, de acordo com a Fiocruz Bahia, a iniciativa est&aacute; alinhada &agrave; meta da <strong>Organiza&ccedil;&atilde;o Pan-Americana da Sa&uacute;de (Opas\/OMS)<\/strong>, que pretende eliminar a transmiss&atilde;o vertical do HTLV-1 at&eacute; 2030.<\/p><p>Al&eacute;m da Fiocruz e do Minist&eacute;rio da Sa&uacute;de, participam do ensaio cl&iacute;nico o Imperial College London, o Laborat&oacute;rio Central de Sa&uacute;de P&uacute;blica da Bahia (Lacen-BA), a Secretaria da Sa&uacute;de do Estado da Bahia (Sesab), a associa&ccedil;&atilde;o de pacientes HTLVida e o Conselho Nacional de Desenvolvimento Cient&iacute;fico e Tecnol&oacute;gico (CNPq).<\/p><p><em>Mat&eacute;ria realizada com informa&ccedil;&otilde;es da Ag&ecirc;ncia Fiocruz de Not&iacute;cias e Ag&ecirc;ncia Brasil.<\/em><\/p><blockquote class=\"instagram-media\" data-instgrm-captioned data-instgrm-permalink=\"https:\/\/www.instagram.com\/reel\/DPALntAjwnf\/?utm_source=ig_embed&amp;utm_campaign=loading\" data-instgrm-version=\"14\" style=\" background:#FFF; border:0; border-radius:3px; box-shadow:0 0 1px 0 rgba(0,0,0,0.5),0 1px 10px 0 rgba(0,0,0,0.15); margin: 1px; max-width:540px; min-width:326px; padding:0; width:99.375%; width:-webkit-calc(100% - 2px); width:calc(100% - 2px);\"><div style=\"padding:16px;\"> <a href=\"https:\/\/www.instagram.com\/reel\/DPALntAjwnf\/?utm_source=ig_embed&amp;utm_campaign=loading\" style=\" background:#FFFFFF; line-height:0; padding:0 0; text-align:center; text-decoration:none; width:100%;\" target=\"_blank\"> <div style=\" display: flex; flex-direction: row; align-items: center;\"> <div style=\"background-color: #F4F4F4; border-radius: 50%; flex-grow: 0; height: 40px; margin-right: 14px; width: 40px;\"><\/div> <div style=\"display: flex; flex-direction: column; flex-grow: 1; justify-content: center;\"> <div style=\" background-color: #F4F4F4; border-radius: 4px; flex-grow: 0; height: 14px; margin-bottom: 6px; width: 100px;\"><\/div> <div style=\" background-color: #F4F4F4; border-radius: 4px; flex-grow: 0; height: 14px; width: 60px;\"><\/div><\/div><\/div><div style=\"padding: 19% 0;\"><\/div> <div style=\"display:block; height:50px; margin:0 auto 12px; width:50px;\"><svg width=\"50px\" height=\"50px\" viewbox=\"0 0 60 60\" version=\"1.1\" xmlns=\"https:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"https:\/\/www.w3.org\/1999\/xlink\"><g stroke=\"none\" stroke-width=\"1\" fill=\"none\" fill-rule=\"evenodd\"><g transform=\"translate(-511.000000, -20.000000)\" fill=\"#000000\"><g><path d=\"M556.869,30.41 C554.814,30.41 553.148,32.076 553.148,34.131 C553.148,36.186 554.814,37.852 556.869,37.852 C558.924,37.852 560.59,36.186 560.59,34.131 C560.59,32.076 558.924,30.41 556.869,30.41 M541,60.657 C535.114,60.657 530.342,55.887 530.342,50 C530.342,44.114 535.114,39.342 541,39.342 C546.887,39.342 551.658,44.114 551.658,50 C551.658,55.887 546.887,60.657 541,60.657 M541,33.886 C532.1,33.886 524.886,41.1 524.886,50 C524.886,58.899 532.1,66.113 541,66.113 C549.9,66.113 557.115,58.899 557.115,50 C557.115,41.1 549.9,33.886 541,33.886 M565.378,62.101 C565.244,65.022 564.756,66.606 564.346,67.663 C563.803,69.06 563.154,70.057 562.106,71.106 C561.058,72.155 560.06,72.803 558.662,73.347 C557.607,73.757 556.021,74.244 553.102,74.378 C549.944,74.521 548.997,74.552 541,74.552 C533.003,74.552 532.056,74.521 528.898,74.378 C525.979,74.244 524.393,73.757 523.338,73.347 C521.94,72.803 520.942,72.155 519.894,71.106 C518.846,70.057 518.197,69.06 517.654,67.663 C517.244,66.606 516.755,65.022 516.623,62.101 C516.479,58.943 516.448,57.996 516.448,50 C516.448,42.003 516.479,41.056 516.623,37.899 C516.755,34.978 517.244,33.391 517.654,32.338 C518.197,30.938 518.846,29.942 519.894,28.894 C520.942,27.846 521.94,27.196 523.338,26.654 C524.393,26.244 525.979,25.756 528.898,25.623 C532.057,25.479 533.004,25.448 541,25.448 C548.997,25.448 549.943,25.479 553.102,25.623 C556.021,25.756 557.607,26.244 558.662,26.654 C560.06,27.196 561.058,27.846 562.106,28.894 C563.154,29.942 563.803,30.938 564.346,32.338 C564.756,33.391 565.244,34.978 565.378,37.899 C565.522,41.056 565.552,42.003 565.552,50 C565.552,57.996 565.522,58.943 565.378,62.101 M570.82,37.631 C570.674,34.438 570.167,32.258 569.425,30.349 C568.659,28.377 567.633,26.702 565.965,25.035 C564.297,23.368 562.623,22.342 560.652,21.575 C558.743,20.834 556.562,20.326 553.369,20.18 C550.169,20.033 549.148,20 541,20 C532.853,20 531.831,20.033 528.631,20.18 C525.438,20.326 523.257,20.834 521.349,21.575 C519.376,22.342 517.703,23.368 516.035,25.035 C514.368,26.702 513.342,28.377 512.574,30.349 C511.834,32.258 511.326,34.438 511.181,37.631 C511.035,40.831 511,41.851 511,50 C511,58.147 511.035,59.17 511.181,62.369 C511.326,65.562 511.834,67.743 512.574,69.651 C513.342,71.625 514.368,73.296 516.035,74.965 C517.703,76.634 519.376,77.658 521.349,78.425 C523.257,79.167 525.438,79.673 528.631,79.82 C531.831,79.965 532.853,80.001 541,80.001 C549.148,80.001 550.169,79.965 553.369,79.82 C556.562,79.673 558.743,79.167 560.652,78.425 C562.623,77.658 564.297,76.634 565.965,74.965 C567.633,73.296 568.659,71.625 569.425,69.651 C570.167,67.743 570.674,65.562 570.82,62.369 C570.966,59.17 571,58.147 571,50 C571,41.851 570.966,40.831 570.82,37.631\"><\/path><\/g><\/g><\/g><\/svg><\/div><div style=\"padding-top: 8px;\"> <div style=\" color:#3897f0; font-family:Arial,sans-serif; font-size:14px; font-style:normal; font-weight:550; line-height:18px;\">Ver essa foto no Instagram<\/div><\/div><div style=\"padding: 12.5% 0;\"><\/div> <div style=\"display: flex; flex-direction: row; margin-bottom: 14px; align-items: center;\"><div> <div style=\"background-color: #F4F4F4; border-radius: 50%; height: 12.5px; width: 12.5px; transform: translateX(0px) translateY(7px);\"><\/div> <div style=\"background-color: #F4F4F4; height: 12.5px; transform: rotate(-45deg) translateX(3px) translateY(1px); width: 12.5px; flex-grow: 0; margin-right: 14px; margin-left: 2px;\"><\/div> <div style=\"background-color: #F4F4F4; border-radius: 50%; height: 12.5px; width: 12.5px; transform: translateX(9px) translateY(-18px);\"><\/div><\/div><div style=\"margin-left: 8px;\"> <div style=\" background-color: #F4F4F4; border-radius: 50%; flex-grow: 0; height: 20px; width: 20px;\"><\/div> <div style=\" width: 0; height: 0; border-top: 2px solid transparent; border-left: 6px solid #f4f4f4; border-bottom: 2px solid transparent; transform: translateX(16px) translateY(-4px) rotate(30deg)\"><\/div><\/div><div style=\"margin-left: auto;\"> <div style=\" width: 0px; border-top: 8px solid #F4F4F4; border-right: 8px solid transparent; transform: translateY(16px);\"><\/div> <div style=\" background-color: #F4F4F4; flex-grow: 0; height: 12px; width: 16px; transform: translateY(-4px);\"><\/div> <div style=\" width: 0; height: 0; border-top: 8px solid #F4F4F4; border-left: 8px solid transparent; transform: translateY(-4px) translateX(8px);\"><\/div><\/div><\/div> <div style=\"display: flex; flex-direction: column; flex-grow: 1; justify-content: center; margin-bottom: 24px;\"> <div style=\" background-color: #F4F4F4; border-radius: 4px; flex-grow: 0; height: 14px; margin-bottom: 6px; width: 224px;\"><\/div> <div style=\" background-color: #F4F4F4; border-radius: 4px; flex-grow: 0; height: 14px; width: 144px;\"><\/div><\/div><\/a><p style=\" color:#c9c8cd; font-family:Arial,sans-serif; font-size:14px; line-height:17px; margin-bottom:0; margin-top:8px; overflow:hidden; padding:8px 0 7px; text-align:center; text-overflow:ellipsis; white-space:nowrap;\"><a href=\"https:\/\/www.instagram.com\/reel\/DPALntAjwnf\/?utm_source=ig_embed&amp;utm_campaign=loading\" style=\" color:#c9c8cd; font-family:Arial,sans-serif; font-size:14px; font-style:normal; font-weight:normal; line-height:17px; text-decoration:none;\" target=\"_blank\">Uma publica&ccedil;&atilde;o compartilhada por Estrate&#769;gia MED (@estrategiamed)<\/a><\/p><\/div><\/blockquote><script async src=\"\/\/www.instagram.com\/embed.js\"><\/script><p>Para n&atilde;o perder nenhuma atualiza&ccedil;&atilde;o no universo da medicina e ficar por dentro dos seletivos de Resid&ecirc;ncia M&eacute;dica, de revalida&ccedil;&atilde;o de diplomas e conte&uacute;dos t&eacute;cnicos, continue acessando o&nbsp;<a href=\"https:\/\/med.estrategia.com\/portal\/\">Portal do Estrat&eacute;gia MED<\/a>!<\/p><p>\n\n\n\n<a id=\"cta\" class=\"cta-imagem\" href=\"https:\/\/med.estrategia.com\/cursos\/\" target=\"blank\">\n                <img decoding=\"async\" width=\"100%\" src=\"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2025\/08\/estrategia_geral.jpg\" alt=\"\" title=\"estrategia_geral\">\n        <\/a>\n<\/p><\/p>\n","protected":false},"excerpt":{"rendered":"Fiocruz Bahia e Minist\u00e9rio da Sa\u00fade lideram ensaio cl\u00ednico com gestantes e rec\u00e9m-nascidos expostos ao v\u00edrus\n","protected":false},"author":39,"featured_media":95469,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"wl_entities_gutenberg":"","footnotes":""},"categories":[300],"tags":[],"wl_entity_type":[199],"class_list":{"0":"post-95468","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-noticias","8":"wl_entity_type-article"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.6 (Yoast SEO v26.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Estudo in\u00e9dito testa Dolutegravir contra transmiss\u00e3o vertical do HTLV-1<\/title>\n<meta name=\"description\" content=\"Saiba mais sobre o estudo in\u00e9dito brasileiro que visa diminuir o risco de transmiss\u00e3o vertical do HTLV-1. Confira!\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estudo in\u00e9dito testa Dolutegravir contra transmiss\u00e3o vertical do HTLV-1\" \/>\n<meta property=\"og:description\" content=\"Saiba mais sobre o estudo in\u00e9dito brasileiro que visa diminuir o risco de transmiss\u00e3o vertical do HTLV-1. Confira!\" \/>\n<meta property=\"og:url\" content=\"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/\" \/>\n<meta property=\"og:site_name\" content=\"Estrat\u00e9gia MED\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/estrategiamed1\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-24T22:42:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-24T23:13:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2025\/09\/mulher-gravida-que-toca-em-sua-barriga.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ana Carolina Damasceno\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@estrategiamed_\" \/>\n<meta name=\"twitter:site\" content=\"@estrategiamed_\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ana Carolina Damasceno\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/\",\"url\":\"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/\",\"name\":\"Estudo in\u00e9dito testa Dolutegravir contra transmiss\u00e3o vertical do HTLV-1\",\"isPartOf\":{\"@id\":\"https:\/\/med.estrategia.com\/portal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2025\/09\/mulher-gravida-que-toca-em-sua-barriga.jpg\",\"datePublished\":\"2025-09-24T22:42:52+00:00\",\"dateModified\":\"2025-09-24T23:13:41+00:00\",\"author\":{\"@id\":\"https:\/\/med.estrategia.com\/portal\/#\/schema\/person\/2f553adbb8e25fe39d145c5b2927f58c\"},\"description\":\"Saiba mais sobre o estudo in\u00e9dito brasileiro que visa diminuir o risco de transmiss\u00e3o vertical do HTLV-1. Confira!\",\"breadcrumb\":{\"@id\":\"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/#primaryimage\",\"url\":\"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2025\/09\/mulher-gravida-que-toca-em-sua-barriga.jpg\",\"contentUrl\":\"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2025\/09\/mulher-gravida-que-toca-em-sua-barriga.jpg\",\"width\":1920,\"height\":1280,\"caption\":\"Freepik\/yanalya\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/med.estrategia.com\/portal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Not\u00edcias\",\"item\":\"https:\/\/med.estrategia.com\/portal\/noticias\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Estudo in\u00e9dito testa Dolutegravir contra transmiss\u00e3o vertical do HTLV-1\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/med.estrategia.com\/portal\/#website\",\"url\":\"https:\/\/med.estrategia.com\/portal\/\",\"name\":\"Estrat\u00e9gia MED\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/med.estrategia.com\/portal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/med.estrategia.com\/portal\/#\/schema\/person\/2f553adbb8e25fe39d145c5b2927f58c\",\"name\":\"Ana Carolina Damasceno\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\/\/med.estrategia.com\/portal\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2021\/09\/WhatsApp-Image-2023-08-18-at-16.46.43-150x150.jpeg\",\"contentUrl\":\"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2021\/09\/WhatsApp-Image-2023-08-18-at-16.46.43-150x150.jpeg\",\"caption\":\"Ana Carolina Damasceno\"},\"description\":\"Coordenadora de Jornalismo EMED. Comunicadora por natureza e forma\u00e7\u00e3o, que ama e perde a no\u00e7\u00e3o do tempo com m\u00fasica e s\u00e9rie.\",\"url\":\"https:\/\/med.estrategia.com\/portal\/author\/ana-carolina-damasceno\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Estudo in\u00e9dito testa Dolutegravir contra transmiss\u00e3o vertical do HTLV-1","description":"Saiba mais sobre o estudo in\u00e9dito brasileiro que visa diminuir o risco de transmiss\u00e3o vertical do HTLV-1. Confira!","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/","og_locale":"pt_BR","og_type":"article","og_title":"Estudo in\u00e9dito testa Dolutegravir contra transmiss\u00e3o vertical do HTLV-1","og_description":"Saiba mais sobre o estudo in\u00e9dito brasileiro que visa diminuir o risco de transmiss\u00e3o vertical do HTLV-1. Confira!","og_url":"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/","og_site_name":"Estrat\u00e9gia MED","article_publisher":"https:\/\/www.facebook.com\/estrategiamed1","article_published_time":"2025-09-24T22:42:52+00:00","article_modified_time":"2025-09-24T23:13:41+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2025\/09\/mulher-gravida-que-toca-em-sua-barriga.jpg","type":"image\/jpeg"}],"author":"Ana Carolina Damasceno","twitter_card":"summary_large_image","twitter_creator":"@estrategiamed_","twitter_site":"@estrategiamed_","twitter_misc":{"Escrito por":"Ana Carolina Damasceno","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/","url":"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/","name":"Estudo in\u00e9dito testa Dolutegravir contra transmiss\u00e3o vertical do HTLV-1","isPartOf":{"@id":"https:\/\/med.estrategia.com\/portal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/#primaryimage"},"image":{"@id":"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/#primaryimage"},"thumbnailUrl":"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2025\/09\/mulher-gravida-que-toca-em-sua-barriga.jpg","datePublished":"2025-09-24T22:42:52+00:00","dateModified":"2025-09-24T23:13:41+00:00","author":{"@id":"https:\/\/med.estrategia.com\/portal\/#\/schema\/person\/2f553adbb8e25fe39d145c5b2927f58c"},"description":"Saiba mais sobre o estudo in\u00e9dito brasileiro que visa diminuir o risco de transmiss\u00e3o vertical do HTLV-1. Confira!","breadcrumb":{"@id":"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/#primaryimage","url":"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2025\/09\/mulher-gravida-que-toca-em-sua-barriga.jpg","contentUrl":"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2025\/09\/mulher-gravida-que-toca-em-sua-barriga.jpg","width":1920,"height":1280,"caption":"Freepik\/yanalya"},{"@type":"BreadcrumbList","@id":"https:\/\/med.estrategia.com\/portal\/noticias\/estudo-inedito-testa-dolutegravir-contra-transmissao-vertical-do-htlv-1\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/med.estrategia.com\/portal\/"},{"@type":"ListItem","position":2,"name":"Not\u00edcias","item":"https:\/\/med.estrategia.com\/portal\/noticias\/"},{"@type":"ListItem","position":3,"name":"Estudo in\u00e9dito testa Dolutegravir contra transmiss\u00e3o vertical do HTLV-1"}]},{"@type":"WebSite","@id":"https:\/\/med.estrategia.com\/portal\/#website","url":"https:\/\/med.estrategia.com\/portal\/","name":"Estrat\u00e9gia MED","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/med.estrategia.com\/portal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Person","@id":"https:\/\/med.estrategia.com\/portal\/#\/schema\/person\/2f553adbb8e25fe39d145c5b2927f58c","name":"Ana Carolina Damasceno","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/med.estrategia.com\/portal\/#\/schema\/person\/image\/","url":"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2021\/09\/WhatsApp-Image-2023-08-18-at-16.46.43-150x150.jpeg","contentUrl":"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2021\/09\/WhatsApp-Image-2023-08-18-at-16.46.43-150x150.jpeg","caption":"Ana Carolina Damasceno"},"description":"Coordenadora de Jornalismo EMED. Comunicadora por natureza e forma\u00e7\u00e3o, que ama e perde a no\u00e7\u00e3o do tempo com m\u00fasica e s\u00e9rie.","url":"https:\/\/med.estrategia.com\/portal\/author\/ana-carolina-damasceno\/"}]}},"_wl_alt_label":[],"wl:entity_url":"\/post\/fiocruz-e-ministerio-da-saude-iniciam-ensaio-clinico-pioneiro-para-prevenir-transmissao-vertical-do-htlv-1-no-brasil-95468","_links":{"self":[{"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/posts\/95468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/users\/39"}],"replies":[{"embeddable":true,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/comments?post=95468"}],"version-history":[{"count":5,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/posts\/95468\/revisions"}],"predecessor-version":[{"id":95476,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/posts\/95468\/revisions\/95476"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/media\/95469"}],"wp:attachment":[{"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/media?parent=95468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/categories?post=95468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/tags?post=95468"},{"taxonomy":"wl_entity_type","embeddable":true,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/wl_entity_type?post=95468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}